NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Pyrrhonian,

Cellular therapy became a national priority in Great Britain when the DCVax-L trial became designated as such. Since that time, government funding there has begun to be used to increase cellular therapy production capacity with the building of new facilities. Granted the multipurpose nature does not directly tie in to NWBO but the fact that their readiness seems to be coinciding with Phase 3 completion should not be overlooked. Most other cellular therapies are many years away from commercial production launch let alone capacity and would need others to fill the gaps for them in a fairly big way if and when they do come online. Even those who do have nearer term anticipated production runs are expecting very low quantities compared to what most investor expectations have been. Why? NWBO, through Cognate, does not have the same expected wait time for ramp up so with Great Britain bringing capacity on line fairly quickly we need to be thinking about why there is an obvious priority based need for this right now especially when others seem to have their low expectation runs already covered.